Sector News

Boston Scientific elects Yoshiaki Fujimori to Board

July 13, 2016
Life sciences

Boston Scientific Corporation announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately.

Yoshiaki Fujimori is an adviser to the LIXIL Group Corporation (“LIXIL”), for which he served as president and chief executive officer from 2011 to 2016. Prior to joining LIXIL, Mr. Fujimori spent 25 years with GE, including positions as senior vice president and chief executive officer (CEO) of a number of Asian and global business divisions, including Medical Systems, Plastics and Capital, and was a member of the Corporate Executive Council before serving as chairman, president and CEO of GE Japan for more than three years. Mr. Fujimori started his career at Japanese trading company Nissho Iwai Corporation (now Sojitz).

Mr. Fujimori serves as an external director of Tokyo Electric Power Company, a role he has held since June 2012. He is also an external director for Takeda Pharmaceutical Company Limited. He previously served as chairman of the Japan Construction Material & Housing Equipment Industries Federation. He received his bachelor’s degree in petroleum engineering from the University of Tokyo and his master’s degree from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the Board of Trustees.

“Fujimori-san is an accomplished business leader and brings significant insights on how large companies plan, execute and compete globally to our Board,” said Mike Mahoney, chief executive officer and chairman of the board, Boston Scientific. “We are delighted to welcome him to the Board.”

Source: Boston Scientific

comments closed

Related News

April 20, 2025

FDA cuts outlined in draft HHS budget

Life sciences

Politico’s Agency IQ reported earlier this month that, due to the Trump administration’s laying off of thousands of staffers, the FDA risked hitting a “trigger,” whereby the FDA could be required to refund industry fees if spending by the agency falls below a certain level.

April 20, 2025

Big pharma pushes for European policy change as tariffs loom

Life sciences

Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump “threaten” billions of planned pharma investments on the continent. A group of 32 pharma companies sent a letter to European Commission (EC) President Ursula von der Leyen listing requests to avoid an exodus of operations.

April 20, 2025

Boehringer Ingelheim announces leadership changes in shareholders’ committee and board

Life sciences

Christian Boehringer, Chairman of the Shareholders’ Committee since 2007, has decided to step down from his position as of June 30, 2025. The Shareholders’ Committee has appointed Hubertus von Baumbach, currently Chairman of the Board of Directors, as his successor from July 1, 2025.

How can we help you?

We're easy to reach